Brokerages expect Affimed NV (NASDAQ:AFMD) to post $6.77 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Affimed’s earnings, with the highest sales estimate coming in at $7.22 million and the lowest estimate coming in at $6.32 million. Affimed posted sales of $650,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 941.5%. The company is scheduled to announce its next earnings report on Tuesday, May 21st.

According to Zacks, analysts expect that Affimed will report full year sales of $37.26 million for the current financial year, with estimates ranging from $2.00 million to $81.03 million. For the next financial year, analysts expect that the business will report sales of $83.43 million, with estimates ranging from $27.30 million to $169.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Affimed.

Affimed (NASDAQ:AFMD) last released its earnings results on Wednesday, March 27th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.34. The company had revenue of $25.96 million for the quarter. Affimed had a negative return on equity of 44.56% and a negative net margin of 87.00%.

Several analysts recently weighed in on AFMD shares. Zacks Investment Research upgraded Affimed from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Thursday, April 4th. ValuEngine downgraded Affimed from a “buy” rating to a “hold” rating in a research report on Friday, March 29th. Leerink Swann started coverage on Affimed in a research report on Thursday, March 28th. They set an “outperform” rating and a $4.17 price objective for the company. Finally, Svb Leerink started coverage on Affimed in a research report on Thursday, March 28th. They set an “outperform” rating and a $8.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $4.99.

AFMD opened at $3.43 on Thursday. The firm has a market cap of $214.00 million, a PE ratio of -9.03 and a beta of 3.23. Affimed has a 52-week low of $1.40 and a 52-week high of $7.35. The company has a current ratio of 3.01, a quick ratio of 3.00 and a debt-to-equity ratio of 0.04.

Hedge funds have recently made changes to their positions in the stock. Stonepine Capital Management LLC bought a new stake in shares of Affimed during the 4th quarter worth $2,221,000. Lindbrook Capital LLC bought a new stake in shares of Affimed during the 4th quarter worth $38,000. Prescott Group Capital Management L.L.C. lifted its position in shares of Affimed by 16.1% during the 4th quarter. Prescott Group Capital Management L.L.C. now owns 190,680 shares of the biopharmaceutical company’s stock worth $593,000 after buying an additional 26,480 shares during the last quarter. FDx Advisors Inc. bought a new stake in shares of Affimed during the 4th quarter worth $87,000. Finally, Bourgeon Capital Management LLC bought a new stake in shares of Affimed during the 1st quarter worth $42,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

See Also: P/E Growth (PEG)

Get a free copy of the Zacks research report on Affimed (AFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.